Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

Friedländer, Michael; C. Hancock, K.; B. Benigno, Benedict; Rischin, Danny; Messing, Mark; Allen Stringer, C.; Hseon Tay, Eng; J. Kathman, Steven; M. Matthys, Gemma; Lager, Joanne

doi:10.1200/jco.2007.25.18_suppl.5561

Public

Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

Published in Journal of Clinical Oncology • Jun 20, 2007

Authors:

Michael Friedländer

K. C. Hancock

Benedict B. Benigno

Abstract

5561 Background: Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth & inhibits angiogenesis. Clinical studies have demonstrated activity of anti-angiogenesis agents in ovarian carcinoma. Me...

Subject

Pazopanib

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!